ITGB1 Knockout PANC-1 Cell Line

$0.00

The ITGB1 Knockout PANC-1 Cell Line is a CRISPR/Cas9-edited human pancreatic cancer cell model for studying integrin ??1 (ITGB1) function. ITGB1 encodes a cell adhesion receptor that mediates interactions with extracellular matrix proteins, activating downstream pathways involving FAK, Src, PI3K/AKT, and ERK, and regulating processes such as proliferation, survival, and migration.

Derived from a KRAS-mutant pancreatic ductal adenocarcinoma, the PANC-1 background is ideal for investigating integrin-driven metastasis and drug resistance. Applications include cell adhesion and invasion assays, 3D tumor model studies, and phospho-signaling analysis to dissect integrin contributions to oncogenic signaling.

999 in stock

Description

The ITGB1 Knockout PANC-1 Cell Line is a CRISPR/Cas9-edited human pancreatic cancer cell line designed for loss-of-function investigation of integrin beta 1 (ITGB1). Generated by targeted disruption of the ITGB1 gene in PANC-1 cells, this constitutive knockout model abrogates ITGB1 protein expression and downstream integrin ??1-mediated functions. It provides a robust system to study adhesion signaling, tumor progression, and drug response mechanisms in a pancreatic ductal adenocarcinoma context.

PANC-1 is a KRAS, TP53, and CDKN2A-mutant pancreatic carcinoma cell line derived from a 56-year-old male. It serves as a clinically relevant model of pancreatic cancer possessing high invasive and metastatic potential. The cell line??s dependency on integrin-mediated adhesion makes it a valid platform to interrogate ITGB1-dependent phenotypes, given its expression of the ??1 integrin subunit and capacity for ECM interactions critical for tumor cell dissemination.

ITGB1 heterodimerizes with multiple ?? integrins (e.g., ITGA1-6, ITGAV) to bind ECM ligands including fibronectin, collagens, and laminins. Ligand engagement recruits talin and kindlin, which activate FAK and Src, triggering the PI3K/AKT and MAPK/ERK cascades. Downstream, Rho GTPases (RhoA, Rac1) reorganize the actin cytoskeleton, while transcription factors AP-1 and NF-??B drive expression of MMPs, cyclin D1, Bcl-2, and Snail. ITGB1 signaling integrates with growth factor cues via co-receptors such as EGFR and is modulated by tetraspanins CD9 and CD81.

In PANC-1 cells, ITGB1 knockout disrupts adhesion to fibronectin and collagen, attenuating FAK and ERK phosphorylation and reducing survival and proliferative outputs. Impaired migration and invasion are anticipated, given the integrin??s role in actin-based motility. In a KRAS-driven tumor model, the absence of ITGB1 signaling may uncouple matrix-dependent survival cues, offering a tool to examine integrin dependence in oncogenic signaling and potential synergies with gemcitabine therapy.

This knockout line is applicable in adhesion, spreading, and migration assays on defined ECM substrates, Boyden chamber invasion assays, and 3D spheroid cultures. Downstream analyses include Western blot detection of phospho-FAK/ERK, immunofluorescence labeling of focal adhesion proteins, RNA-seq transcriptomics, and drug sensitivity testing. Proliferation and apoptosis assays further define the integrin contribution to cell growth. For additional technical specifications or ordering inquiries, please contact Ascent Research.

Additional information

Product Type

In Stock Cell Lines

Species

Homo sapiens (Human)

Tissue Source

Pancreas

Disease

Epithelioid carcinoma

Size/Quantity

1 million

Shipping info

Cryopreserved in vials and shipped on dry ice

Host Cell

PANC-1

Sex of Donor

Male

Age

56 years

Gene Name

ITGB1

Gene Identifier

NCBI Gene ID 3688

Morphology

Epithelial-like

Growth Mode

Adherent

Storage

Liquid nitrogen (LN2)

Temperature

37

Atmosphere

5% CO2

Sterility testing

The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Mycoplasma testing

Negative for mycoplasma through PCR analysis

Reviews

There are no reviews yet.

Be the first to review “ITGB1 Knockout PANC-1 Cell Line”

Your email address will not be published. Required fields are marked *